Lenalidomide maintenance in high risk chronic lymphocytic leukaemia: practice changing study or hypothesis generating approach?

被引：0
作者：
Rossi, Davide [1 ]
Condoluci, Adalgisa [2 ]
机构：
[1] Inst Oncol Res, Dept Hematol, CH-6500 Bellinzona, Switzerland
[2] Inst Southern Switzerland, Oncol, CH-6500 Bellinzona, Switzerland
来源：
LANCET HAEMATOLOGY | 2017年 / 4卷 / 10期
关键词：
PROGRESSION-FREE; THERAPY; TRIAL; SURVIVAL;
D O I：
10.1016/S2352-3026(17)30178-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E455 / E456
页数：2
相关论文
共 24 条
  • [1] Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
    Sher, Taimur
    Miller, Kena C.
    Lawrence, David
    Whitworth, Amy
    Hernandez-Ilizaliturri, Francisco
    Czuczman, Myron S.
    Miller, Austin
    Lawrence, William
    Bilgram, Syed Ali
    Sood, Raman
    Wood, Margaret T.
    Block, Annemarie W.
    Lee, Kelvin
    Chanan-Khan, Asher Alban
    LEUKEMIA & LYMPHOMA, 2010, 51 (01) : 85 - 88
  • [2] Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
    Fink, Anna Maria
    Bahlo, Jasmin
    Robrecht, Sandra
    Al-Sawaf, Othman
    Aldaoud, Ali
    Hebart, Holger
    Jentsch-Ullrich, Kathleen
    Doerfel, Steffen
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Noesslinger, Thomas
    Ghia, Paolo
    Bosch, Francesc
    Kater, Arnon P.
    Dohner, Hartmut
    Kneba, Michael
    Kreuzer, Karl-Anton
    Tausch, Eugen
    Stilgenbauer, Stephan
    Ritgen, Matthias
    Boettcher, Sebastian
    Eichhorst, Barbara
    Hallek, Michael
    LANCET HAEMATOLOGY, 2017, 4 (10): : E475 - E486
  • [3] Chronic lymphocytic leukaemia: An updated approach to diagnosis and management in general practice
    Tomlinson, Ross
    AUSTRALIAN FAMILY PHYSICIAN, 2017, 46 (07) : 493 - 496
  • [4] Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia
    Kuss, Bryone J.
    Tam, Constantine S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 5 - 10
  • [5] Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia
    Thangavadivel, Shanmugapriya
    Zhao, Qiuhong
    Epperla, Narendranath
    Rike, Lindsey
    Mo, Xiaokui
    Badawi, Mohamed
    Bystry, Darlene M.
    Phelps, Mitch A.
    Andritsos, Leslie A.
    Rogers, Kerry A.
    Jones, Jeffrey
    Woyach, Jennifer A.
    Byrd, John C.
    Awan, Farrukh T.
    CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6187 - 6195
  • [6] Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
    Egle, Alexander
    Steurer, Michael
    Melchardt, Thomas
    Weiss, Lukas
    Gassner, Franz Josef
    Zaborsky, Nadja
    Geisberger, Roland
    Catakovic, Kemal
    Hartmann, Tanja Nicole
    Pleyer, Lisa
    Voskova, Daniela
    Thaler, Josef
    Lang, Alois
    Girschikofsky, Michael
    Petzer, Andreas
    Greil, Richard
    ANNALS OF HEMATOLOGY, 2018, 97 (10) : 1825 - 1839
  • [7] Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission
    Abou Dalle, Iman
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Daver, Naval
    Wang, Xuemei
    Jabbour, Elias
    Estrov, Zeev
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Ferrajoli, Alessandra
    Jain, Nitin
    Wang, Sa A.
    Jammal, Nadya
    Borthakur, Gautam
    Naqvi, Kiran
    Pelletier, Sarah
    Pierce, Sherry
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Kadia, Tapan M.
    CANCER, 2021, 127 (11) : 1894 - 1900
  • [8] Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach
    Zent, Clive S.
    Kay, Neil E.
    LEUKEMIA & LYMPHOMA, 2011, 52 (08) : 1425 - 1434
  • [9] Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
    van Oers, Marinus H. J.
    Kuliczkowski, Kazimierz
    Smolej, Lukas
    Petrini, Mario
    Offner, Fritz
    Grosicki, Sebastian
    Levin, Mark-David
    Gupta, Ira
    Phillips, Jennifer
    Williams, Vanessa
    Manson, Stephanie
    Lisby, Steen
    Geisler, Christian
    LANCET ONCOLOGY, 2015, 16 (13) : 1370 - 1379
  • [10] A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome
    Koo, Ray Mun
    Wong, Eric
    Davis, Joanne E.
    Perera, Travis
    Lim, Andrew
    Koldej, Rachel M.
    Ritchie, David S.
    BONE MARROW TRANSPLANTATION, 2024, 59 (07) : 1025 - 1027
123